TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18424129

Group type: EXPERIMENTAL
Intervention: (123)I‐mIBG positive metastatic disease after four chemotherapy cycles
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: (123)I‐mIBG positive metastatic disease after six chemotherapy cycles
Number of subjects: 113
Study: 17065540

Group type: EXPERIMENTAL
Intervention: Patient education intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 12836088

Group type: EXPERIMENTAL
Intervention: Active Reliefband
Number of subjects: 49
Study: 11218246

Group type: EXPERIMENTAL
Intervention: Interferon-alpha2b (IFN-alpha2b) treatment
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 88
Study: 9299856

Group type: EXPERIMENTAL
Intervention: Aspirin and dipyridamole (group B)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Plasma exchange and steroids without antiplatelet agents (group A)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ticlopidine maintenance therapy (after disease remission)
Number of subjects: 72
Study: 8467430

Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride (100 mg, single oral dose)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 3537251

Group type: EXPERIMENTAL
Intervention: 100 ng/kg/day ethinyl estradiol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30292589

Group type: EXPERIMENTAL
Intervention: Lixisenatide (10-20 μg daily subcutaneous injection)
Number of subjects: 6068

Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 6068

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6068
Study: 26848931

Group type: EXPERIMENTAL
Intervention: Maternal micronutrient supplementation during pregnancy
Number of subjects: 0
Study: 24893311

Group type: EXPERIMENTAL
Intervention: Bipolar transurethral bladder tumor resection
Number of subjects: 8188

Group type: COMPARATOR
Intervention: Monopolar transurethral bladder tumor resection
Number of subjects: 8188
Study: 22943927

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Combined therapy (fenofibrate and atorvastatin)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Therapeutic lifestyle change
Number of subjects: 67
Study: 20730858

Group type: EXPERIMENTAL
Intervention: Fibrin sealant (EVICEL(™) Fibrin Sealant (Human))
Number of subjects: 147

Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 147
Study: 18812609

Group type: EXPERIMENTAL
Intervention: Intravenous CNTO 528
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 16023466

Group type: EXPERIMENTAL
Intervention: Plugs made out of Microcell Puff Lite or Plastazote Medium, 40 mm width, placed at peak pressure sites
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Pressure based placement, 40 x 20 mm, Plastazote Medium
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control midsoles manufactured using Microcell Puff
Number of subjects: 5
Study: 14761128

Group type: EXPERIMENTAL
Intervention: Terbinafine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Griseofulvin
Number of subjects: 0
Study: 10665890

Group type: EXPERIMENTAL
Intervention: Replication of the self‐management program developed at a university medical center
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified version of the self‐management program including only the core elements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual-care program
Number of subjects: 0
Study: 8909669

Group type: EXPERIMENTAL
Intervention: Subcutaneous morphine (0.15 mg/kg)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Intramuscular morphine (0.15 mg/kg)
Number of subjects: 59
Study: 2483556

Group type: EXPERIMENTAL
Intervention: Radical radiation and combination of bleomycin and 5-fluorouracil (5-FU)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Radical radiation alone
Number of subjects: 74
Study: 72953

Group type: EXPERIMENTAL
Intervention: Preoperative lincomycin and tobramycin
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Local instillation of povidone-iodine
Number of subjects: 113

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 113
Study: 31087729

Group type: EXPERIMENTAL
Intervention: Single-use negative pressure wound therapy (s-NPWT)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Traditional negative pressure wound therapy (t-NPWT)
Number of subjects: 164
Study: 28225506

Group type: EXPERIMENTAL
Intervention: 400 mg IV ibuprofen in 100 mL saline
Number of subjects: 60

Group type: COMPARATOR
Intervention: 100 mL saline solution
Number of subjects: 60
Study: 26188456

Group type: EXPERIMENTAL
Intervention: Increased social control treatment (participants played in randomly assigned pairs of two)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feedback on unethical behavior of participants in a similar experiment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Online experiment with increased anonymity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline treatment (subjects rolled a die in private)
Number of subjects: 0
Study: 23004005

Group type: EXPERIMENTAL
Intervention: Peironimev‐plus/oral/one tablet‐daily + Verapamil injection (peri‐lesional) 10 mg/every two weeks + Verapamil iontophoresis/5 mg/three times a week for 6 months
Number of subjects: 64

Group type: COMPARATOR
Intervention: Verapamil injection (peri‐lesional) 10 mg/every two weeks + Verapamil iontophoresis/5 mg/three times a week for 6 months
Number of subjects: 64
Study: 21175732

Group type: EXPERIMENTAL
Intervention: Short course and planned medical consultations
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Short course and shared care setting with no planned consultations
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Short course and planned nursing consultations every 3 months
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Short course and consultations with nurses and hospital doctors
Number of subjects: 33
Study: 19843915

Group type: COMPARATOR
Intervention: Circumferential pulmonary vein ablation (CPVA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pulmonary vein antrum isolation (PVAI)
Number of subjects: 60
Study: 21940760

Group type: EXPERIMENTAL
Intervention: CX717 1000 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 15699235

Group type: EXPERIMENTAL
Intervention: Mothers and infants received vitamin A (Aa)
Number of subjects: 9208

Group type: EXPERIMENTAL
Intervention: Mothers received vitamin A and infants received placebo (Ap)
Number of subjects: 9208

Group type: EXPERIMENTAL
Intervention: Mothers received placebo and infants received vitamin A (Pa)
Number of subjects: 9208

Group type: COMPARATOR
Intervention: Both mothers and infants received placebo (Pp)
Number of subjects: 9208
Study: 14563516

Group type: EXPERIMENTAL
Intervention: Prophylactic platelet transfusion at a threshold of 10,000/microL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylactic platelet transfusion at a threshold of 20,000/microL
Number of subjects: 0
Study: 11477926

Group type: EXPERIMENTAL
Intervention: Puerarin
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control
Number of subjects: 39
Study: 8080670

Group type: EXPERIMENTAL
Intervention: Dipyrone 1 g every 8 h (n = 41)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Dipyrone 2 g every 8 h (n = 38)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Morphine 10 mg every 4 h (n = 42)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Dipyrone (1 g or 2 g)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 121
Study: 2583144

Group type: COMPARATOR
Intervention: Water placebo (WP)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 6% sucrose with electrolytes
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 8% sucrose with electrolytes
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10% sucrose with electrolytes
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CHO beverages (6%, 8%, 10% sucrose)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All beverage treatments
Number of subjects: 12
Study: 338198

Group type: EXPERIMENTAL
Intervention: Elevated levels of antibodies to milk proteins in infants fed cow milk.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Children with food hypersensitivity (age-matched to non-hypersensitive children).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypersensitivity to food (not necessarily milk).
Number of subjects: 0
Study: 28526210

Group type: EXPERIMENTAL
Intervention: Montelukast 4 mg daily for 48 weeks
Number of subjects: 93

Group type: COMPARATOR
Intervention: As-needed β2-agonists
Number of subjects: 93
Study: 27617317

Group type: COMPARATOR
Intervention: Tamsulosin 0.4 mg
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 85
Study: 24745852

Group type: EXPERIMENTAL
Intervention: Group A - Needle insertion at intervertebral space determined by intercristal line intersecting an intervertebral space or spinous process above
Number of subjects: 110

Group type: COMPARATOR
Intervention: Group B - Needle insertion at intervertebral space determined by intercristal line intersecting an intervertebral space or spinous process below
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 110

Group type: COMPARATOR
Intervention: Group B
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Group A and Group B
Number of subjects: 110
Study: 22503005

Group type: EXPERIMENTAL
Intervention: 500 ml increase in dead space through a custom designed full face mask
Number of subjects: 12

Group type: COMPARATOR
Intervention: No added dead space (control condition)
Number of subjects: 12
Study: 20007752

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 1490

Group type: COMPARATOR
Intervention: Medically treated patients with high-grade stenosis
Number of subjects: 1490

Group type: EXPERIMENTAL
Intervention: Patients with CKD
Number of subjects: 1490
Study: 18334528

Group type: EXPERIMENTAL
Intervention: Baseline plasma adiponectin (ADPN) levels
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Yearly plasma ADPN levels
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Baseline ADPN levels
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: ADPN levels measured over time
Number of subjects: 182
Study: 16299869

Group type: EXPERIMENTAL
Intervention: Videotape and brochure with practical skills for self-control and treatment
Number of subjects: 332

Group type: COMPARATOR
Intervention: Videotape and brochure with general diabetes information
Number of subjects: 332

Group type: COMPARATOR
Intervention: Traditional treatment
Number of subjects: 332
Study: 12571210

Group type: COMPARATOR
Intervention: Radioiodine (RAI) administered at a dose of 12,580 kBq/mL of nodular volume (NV)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Percutaneous ethanol injection (PEI) followed by radioiodine (RAI)
Number of subjects: 22
Study: 10353578

Group type: EXPERIMENTAL
Intervention: 200 microg of budesonide Turbuhaler administered twice daily
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: 400 microg of budesonide Turbuhaler administered twice daily
Number of subjects: 273

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 273
Study: 8575948

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch (21 mg to 14 mg to 7 mg, each for 30 days)
Number of subjects: 110
Study: 1680600

Group type: EXPERIMENTAL
Intervention: Propranolol (0.15 mg kg‐1 i.v.) during exercise
Number of subjects: 19

Group type: COMPARATOR
Intervention: Graded arm exercise
Number of subjects: 19

Group type: COMPARATOR
Intervention: Prolonged leg exercise
Number of subjects: 19
Study: 6989437

Group type: EXPERIMENTAL
Intervention: Five to six year programme of medical examinations and intervention to reduce coronary risk factors.
Number of subjects: 18210

Group type: EXPERIMENTAL
Intervention: Advice on dietary reduction of plasma cholesterol, smoking cessation, regular exercise, reduced energy intake for overweight, and hypertension treatment.
Number of subjects: 18210
Study: 31922375

Group type: EXPERIMENTAL
Intervention: I-gel
Number of subjects: 168

Group type: COMPARATOR
Intervention: LMA classic
Number of subjects: 168

Group type: COMPARATOR
Intervention: AIR-Q
Number of subjects: 168
Study: 31061025

Group type: EXPERIMENTAL
Intervention: Nasogastric tube (NGT) feeding
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nasoduodenal tube (NDT) feeding
Number of subjects: 0
Study: 28485692

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0
Study: 25926410

Group type: EXPERIMENTAL
Intervention: Low-fat diet (20% energy)
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: High-fat diet (40% energy)
Number of subjects: 743
Study: 24223927

Group type: EXPERIMENTAL
Intervention: Ketamine (subanesthetic dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21473824

Group type: EXPERIMENTAL
Intervention: BIS guided group
Number of subjects: 105
Study: 19683970

Group type: COMPARATOR
Intervention: EUR-1008 (Zenpep, pancrelipase)
Number of subjects: 53
Study: 17339143

Group type: EXPERIMENTAL
Intervention: Intranasal sumatriptan 20 mg
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 15648502

Group type: EXPERIMENTAL
Intervention: Acrobatics and Balance test
Number of subjects: 493
Study: 10885719

Group type: EXPERIMENTAL
Intervention: Ballooned NJT
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nonballooned NJT
Number of subjects: 30
Study: 9170463

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 141

Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 141
Study: 1443746

Group type: EXPERIMENTAL
Intervention: Droperidol 75 micrograms/kg intravenously
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Lorazepam 10 micrograms/kg intravenously
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 3105506

Group type: EXPERIMENTAL
Intervention: Transdermal Trinitrin (10 mg per 24 hours)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 30863047

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (GLY) 15.6 µg twice daily
Number of subjects: 846

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 846
Study: 30184223

Group type: EXPERIMENTAL
Intervention: FFR + CSB
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: RFR + CSB
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: FFR + MNP
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: CSB
Number of subjects: 574
Study: 27638878

Group type: EXPERIMENTAL
Intervention: Resistance interval (R-INT)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cardio interval (C-INT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Seated control (CTL)
Number of subjects: 12
Study: 24899597

Group type: EXPERIMENTAL
Intervention: 7.5% CO2 inhalation
Number of subjects: 27

Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 27
Study: 22682718

Group type: EXPERIMENTAL
Intervention: Touchscreen educational modules on nutrition and feeding (5 modules)
Number of subjects: 160
Study: 20194521

Group type: EXPERIMENTAL
Intervention: Reduction in smoking (reduced cigarettes per day >50%)
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Quitters
Number of subjects: 539

Group type: COMPARATOR
Intervention: Nonreducers
Number of subjects: 539
Study: 18602187

Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 176

Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 176
Study: 15836660

Group type: EXPERIMENTAL
Intervention: 40 mg atorvastatin + placebo alpha‐tocopherol
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 800 IU alpha‐tocopherol + placebo atorvastatin
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 40 mg atorvastatin + 800 IU alpha‐tocopherol
Number of subjects: 44

Group type: COMPARATOR
Intervention: placebo atorvastatin + placebo alpha‐tocopherol
Number of subjects: 44
Study: 11888030

Group type: EXPERIMENTAL
Intervention: 5 mg of risedronate sodium
Number of subjects: 10068

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10068
Study: 9883220

Group type: EXPERIMENTAL
Intervention: 40 MU of intravesical interferon alpha‐2b (IFN alpha‐2b)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: 60 MU of intravesical interferon alpha‐2b (IFN alpha‐2b)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: 80 MU of intravesical interferon alpha‐2b (IFN alpha‐2b)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Transurethral resection (TUR) alone
Number of subjects: 89
Study: 8564655

Group type: EXPERIMENTAL
Intervention: Normal breathing of 100% O2
Number of subjects: 17

Group type: COMPARATOR
Intervention: Four deep breaths of 100% O2 within 30 seconds
Number of subjects: 17
Study: 2375564

Group type: EXPERIMENTAL
Intervention: Conventional technique (switching needles)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alternative technique (no switching needles)
Number of subjects: 0
Study: 347638

Group type: EXPERIMENTAL
Intervention: Ornithine alpha-ketoglutarate (OAKG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 31472246

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Baduanjin
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Stationary cycling
Number of subjects: 140

Group type: COMPARATOR
Intervention: Health education (control)
Number of subjects: 140
Study: 30396440

Group type: EXPERIMENTAL
Intervention: Exposure to bacteria through cultural practices (e.g., consumption of unboiled milk, access to water sources)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Antimicrobial use in people and livestock
Number of subjects: 391
Study: 27396427

Group type: EXPERIMENTAL
Intervention: SNP rs11615
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: SNPs rs3212986, rs17655, rs1047768
Number of subjects: 374
Study: 24568360

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure treatment for four weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Treatment as usual for four weeks
Number of subjects: 70
Study: 22990178

Group type: EXPERIMENTAL
Intervention: Anesthetic concentration group
Number of subjects: 18836

Group type: EXPERIMENTAL
Intervention: BIS group
Number of subjects: 18836

Group type: COMPARATOR
Intervention: BIS protocol
Number of subjects: 18836

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 18836
Study: 20188795

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: S'/S' genotype
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: L/S' genotype
Number of subjects: 52
Study: 17650170

Group type: EXPERIMENTAL
Intervention: Group I (GI) - Continuous denture wear
Number of subjects: 24

Group type: COMPARATOR
Intervention: Group II (GII) - Daytime denture wear
Number of subjects: 24
Study: 16300126

Group type: EXPERIMENTAL
Intervention: Distal Active Concept therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Untreated subjects (Control)
Number of subjects: 120
Study: 12397459

Group type: EXPERIMENTAL
Intervention: High-dose radioiodine therapy (at least 2.96 GBq iodine-131, maximal administered activity 22.3 GBq)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: High-dose radioiodine therapy
Number of subjects: 88
Study: 15490777

Group type: EXPERIMENTAL
Intervention: Bonding agent/composite combination (Prime & Bond 2.1/PrismaTPH)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Compomer (Dyract)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Light-curing glass ionomer (Fuji II LC)
Number of subjects: 11

Group type: COMPARATOR
Intervention: All materials (P & B/TPH, Dyract, Fuji II LC)
Number of subjects: 11
Study: 7646610

Group type: EXPERIMENTAL
Intervention: Paracervical block with 10 mL of 1% mepivacaine hydrochloride solution (n = 87)
Number of subjects: 177

Group type: COMPARATOR
Intervention: No local anesthesia (n = 90)
Number of subjects: 177
Study: 2912322

Group type: EXPERIMENTAL
Intervention: Clenbuterol delivered via DDS
Number of subjects: 11

Group type: COMPARATOR
Intervention: Clenbuterol delivered via conventional MDI
Number of subjects: 11
Study: 4719668

Group type: EXPERIMENTAL
Intervention: Alum-precipitated M protein vaccine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (aluminum hydroxide adjuvant)
Number of subjects: 38
Study: 105114

Group type: EXPERIMENTAL
Intervention: 0.1 unit/kg regular insulin given intramuscularly every two hours
Number of subjects: 10

Group type: COMPARATOR
Intervention: 1.0 unit/kg regular insulin given half subcutaneously and half intravenously every 4 hours
Number of subjects: 10
Study: 30950904

Group type: EXPERIMENTAL
Intervention: AuraGain
Number of subjects: 100

Group type: COMPARATOR
Intervention: i-gel
Number of subjects: 100
Study: 29450988

Group type: EXPERIMENTAL
Intervention: SBI-H-GSE
Number of subjects: 140

Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 140
Study: 29648726

Group type: EXPERIMENTAL
Intervention: Test formulation of alendronate sodium (70 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference formulation of alendronate sodium (70 mg)
Number of subjects: 0
Study: 24222372

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 22305242

Group type: EXPERIMENTAL
Intervention: Medical leeches (8 leeches)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 52
Study: 19640384

Group type: EXPERIMENTAL
Intervention: Plasma adiponectin
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Plasma leptin
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Plasma C-reactive protein
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: eGFR
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Plasma von Willebrand factor and soluble vascular adhesion molecule-1
Number of subjects: 141
Study: 17251174

Group type: EXPERIMENTAL
Intervention: Hamstring tendon graft
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Patellar tendon graft
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study: 15167309

Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol 2 mg + norethisterone acetate 1 mg (E2/NETA)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Raloxifene HCL 60 mg
Number of subjects: 28